Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
(Date:2/26/2015)... CLEVELAND , Feb. 26, 2015 BioEnterprise ... biomedical companies have attracted more than $2 billion in ... from local and national investors, strategic sources, state – ... Over half of the $2 billion has been raised ... announcement comes on the heels of the BioEnterprise ...
(Date:2/26/2015)... 2015 Already well respected for accuracy, ... expanding its Length Gauge offerings with new variants of ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length gauge series ... Two new 1Vpp, 12mm stroke length variants of the ... is a variant with a weak spring, 0.4N of ...
(Date:2/26/2015)... RURO, Inc., a leading LIMS, RFID and sample ... latest update to the bestselling commercial-off-the-shelf sample management system. ... and easy method to gain better control of sample ... has enhanced the system’s support for those customers who ... records. , "FreezerPro has become the go-to system ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2RURO Releases FreezerPro® version 6.2 2
... of Energy,s Lawrence Berkeley National Laboratory and the ... world,s first all-integrated sensor circuit based on nanowire ... different crystalline materials. Their method can be used ... , Nanostructures made with specific chemical, electronic, ...
... Revenues - a record $35.5 million vs. $24.7 million in Q2 2007 ... - an increase of 43.4%, Q2 2008 Diluted Net Income per Share - ... ... Q2 2007 Q2 2008 New Bookings of $49.0 million vs. $34.5 million in Q2 2007, ...
... Conference, August 3-8, CHICAGO, Aug. 4 Criminal ... to reduce the spread of the virus.,Instead, it increases ... burdening women and other vulnerable groups who,are unable to ... violence,according to a commentary in the August issue of ...
Cached Biology Technology:A first in integrated nanowire sensor circuitry 2A first in integrated nanowire sensor circuitry 3A first in integrated nanowire sensor circuitry 4eResearchTechnology Reports Second Quarter 2008 Results 2eResearchTechnology Reports Second Quarter 2008 Results 3eResearchTechnology Reports Second Quarter 2008 Results 4eResearchTechnology Reports Second Quarter 2008 Results 5eResearchTechnology Reports Second Quarter 2008 Results 6eResearchTechnology Reports Second Quarter 2008 Results 7eResearchTechnology Reports Second Quarter 2008 Results 8eResearchTechnology Reports Second Quarter 2008 Results 9JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission 2JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission 3
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... prevention is worth a pound of cure" can easily ... Because taking off extra weight is an almost insurmountable ... especially childhood, is crucial to realizing optimal long-term health. ... being breastfed might predispose a person to being lean, ...
... The putative skull of Saint Bridget (Birgitta) of Sweden ... is probably not authentic. A new study conducted at Uppsala ... Saint Bridget and her daughter Catherine (Katarina), is not from ... not from the time period when Bridget and Catherine lived. ...
... research of Dr. Doris Taylor was achieved recently when ... agreement with Miromatrix Medical Inc. Dr. Taylor,s research ... that it had created a beating animal heart in ... the promise of one day enabling the replacement of ...
Cached Biology News:Later introduction of baby foods related to lower risk of obesity later in life 2The putative skull of St. Bridget can be questioned 2U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research 2
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
... LYZL6 ( Abpromise for all ... Synthetic peptide: DWLCL AFVE SKFNISKINE ... to amino acids 46-100 of Human ... ID: 57151 ...
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: